Major Comments
The major flaw in this study is the use of the term colonisation that has different meanings in healthy individuals and in COPD. The concept of carriage or colonisation by Streptococcus pneumoniae (SP) refers to nasopharyngeal carriage (reference 4) as collecting sputum samples in large populations is not feasible. The term colonisation in COPD refers to COPD patients have bacteria present in the lower airways even when clinically stable, although this is associated with adverse outcomes and therefore colonisation may not be the correct term. In this study both sputum and nasopharyngeal samples were collected and no data is provided as to the breakdown of the samples. How many samples were sputum, how many were NP swabs in both the positive and negative groups? To further complicate things 6 samples were collected at unscheduled visits that I assume were acute exacerbation visits. If a sputum sample is positive in a patient during an acute exacerbation then it is likely this is the causative agent and the term colonisation is certainly incorrect. Comparing SP colonisation rates with studies in which NP samples only were used is incorrect. The authors should present the data using NP samples only to conform with current concepts of SP carriage/colonisation.
2) COPD patients are defined as having FEV1/FVC ratio <80%. The GOLD definition of COPD is FEV1/FVC ratio <70% and therefore non-COPD patients were included in this study. These should be excluded.
Minor Comments 1) In the Study Design it is described as a 'randomised' study but there is no randomisation and no study groups. 2) In the Introduction it is stated that SP is the most common bacterial aetiological agent of COPD exacerbations and 2 references are provided (2 & 3). One reference is very old and the other is a review of the role of SP and in fact states that it is isolated in 10-15% of exacerbations. Most would agree that Haemophilus influenzae is the commonest bacterial cause of COPD exacerbations.
3) It is stated in the Introduction that colonisation precedes clinical disease but although this is well established for invasive pneumococcal disease it has not been for COPD exacerbations. 4) In the Abstract it is stated that there was no relationship between SP carriage and inhaled therapy but no data on inhaled therapy is provided. 5) The Methods are very brief. There is no information on how samples were obtained, how SP was detected, how exacerbations were defined etc. 6) Presumably there were a large number of exacerbations as the authors state that the exacerbation rate in the SP negative groups was 1.38 per patient. It is stated that only 6 samples were collected at unscheduled visits so what happened at all the other exacerbations? 7) The final section in the Results refers to relationship between COPD severity and SP carriage. The accepted marker of COPD severity is FEV1 % predicted but no data on this is provided in the paper. 8) Presumably the subjects gave informed consent, this should be stated.
REVIEWER
Sanjay Sethi University at Buffalo, SUNY, Buffalo, NY, USA REVIEW RETURNED 16-Oct-2016 GENERAL COMMENTS This is a well designed longitudinal study of S pneumoniae carriage in COPD. The findings are interesting but I have the following comments. The inclusion of patients who are as young as 18 yrs means several patients with asthma were included. Generally, a cutoff of 40 yrs is used to define COPD. However, most of the patients included appear to fit the COPD phenotype. Please add in abstract what type of samples were studied. There are contradictory statements regarding correlation with disease severity in the abstract and in "strengths and limitations". Intro: The most common etiological agent of COPD exacerbations is not S. Pneumoniae. Nasopharyngeal colonization as a precedent to infection is common in children. It is not known if that is the case in adults and in COPD. The sampling in exacerbations was obviously very limited as it appears only 6 exacerbations were studied. The numbers of S. pneumoniae isolated is lower than in other studies. Because of the low numbers, the conclusions drawn may not be reliable.
The findings suggest that S pneumoniae colonization is associated with less exacerbations. There is no explanation provided for this counter-intuitive observation. We have removed all data from unscheduled visits which were associated with COPDrelated hospitalizations therefore those found to be carriers of S. pneumoniae in the paper can be described as being colonised with S. pneumoniae.
In this study both sputum and nasopharyngeal samples were collected and no data is provided as to the breakdown of the samples. How many samples were sputum, how many were NP swabs in both the positive and negative groups?
Response: There is a breakdown of the number of sputum and NP samples provided in figure 1 which is a summary of scheduled study visits. All carriers produced sputum samples (n=15 sputum samples -in one sputum sample, two serotypes of S. pneumoniae were isolated) and non-carriers provided more sputum than NP samples (n= 68% sputum and 32% NP). This data has been added to the paper in the results, page 11, lines 204 to 208.
To further complicate things 6 samples were collected at unscheduled visits that I assume were acute exacerbation visits. If a sputum sample is positive in a patient during an acute exacerbation then it is likely this is the causative agent and the term colonisation is certainly incorrect. Response: All data from unscheduled visits has been removed to avoid any ambiguity between causative agents and colonising agents.
Comparing SP colonisation rates with studies in which NP samples only were used is incorrect.
The authors should present the data using NP samples only to conform with current concepts of SP carriage/colonisation. Response: The majority of samples provided by participants were sputum (69%) and all 16 isolates of S. pneumoniae were isolated from sputum samples. Therefore we cannot omit this data.
Response: We have omitted data for all patients (n=17) recruited who had an FEV1/FVC ratio >70%. Initially, we included patients with a significant smoking history and a clinical history of COPD. As a result we have updated the results presented in all three figures and both tables in the manuscript. Please see tracked changes throughout the manuscript with the data corrections after omission of the 17 patients who had an FEV1/FVC ratio >70%.
Minor Comments 1) In the Study Design it is described as a 'randomised' study but there is no randomisation and no study groups.
Response: This was an error and the term "randomised" has been removed.
2) In the Introduction it is stated that SP is the most common bacterial aetiological agent of COPD exacerbations and 2 references are provided (2 & 3). One reference is very old and the other is a review of the role of SP and in fact states that it is isolated in 10-15% of exacerbations. Most would agree that Haemophilus influenzae is the commonest bacterial cause of COPD exacerbations. Response: SP is one of the most common bacterial causes of COPD exacerbations along with Haemophilus influenza. We have changed the wording of the introduction, page 6, lines 100-101, to state that "Approximately 50-70% of COPD exacerbations are infectious in origin and one of the most common etiological agent is Streptococcus pneumoniae". Furthermore, we have added three more references, one from 2006, 2014 and 2015, to this sentence. Please see the additional references highlighted in the bibliography.
3) It is stated in the Introduction that colonisation precedes clinical disease but although this is well established for invasive pneumococcal disease it has not been for COPD exacerbations. Response: We do not state that SP colonisation precedes COPD exacerbations. We have added the term "invasive" to the sentence in the introduction, page 6, lines 101-103, to say "S. pneumoniae colonises the naso-pharyngeal niche and this colonisation precedes invasive pneumococcal disease".
4)
In the Abstract it is stated that there was no relationship between SP carriage and inhaled therapy but no data on inhaled therapy is provided.
Response: This sentence has been removed.
5) The Methods are very brief. There is no information on how samples were obtained, how SP was detected, how exacerbations were defined etc. Response: The study design and aim section of the methods section has been updated with more information. Please see the tracked changes in "Study design and aim". 6) Presumably there were a large number of exacerbations as the authors state that the exacerbation rate in the SP negative groups was 1.38 per patient. It is stated that only 6 samples were collected at unscheduled visits so what happened at all the other exacerbations? Response: We have removed all data for unscheduled visits. The data on exacerbations was collected from interviews conducted with patients during their scheduled visits. Interviews were conducted a quarterly intervals in the 12-month follow-up period. Exacerbations were recorded if patients reported receiving antibiotics and/or steroids for COPD-related complaints in the period preceding their study visit. Prescription of antibiotics and steroids was confirmed by telephone contact with patients" general practitioners and/or reviewing hospital records. This is described in the methods section on page 8.
7) The final section in the Results refers to relationship between COPD severity and SP carriage. The accepted marker of COPD severity is FEV1 % predicted but no data on this is provided in the paper. Response: We have removed this comment as the numbers are too small for valid analysis.
8) Presumably the subjects gave informed consent, this should be stated. Response: Yes all subjects did provide informed consent. The following sentence has been added to the methods: "Recruitment began in July 2014 and ceased in February 2015 and all patients provided informed consent", page 8, lines 138 to 139.
Reviewer: 2
The inclusion of patients who are as young as 18 yrs means several patients with asthma were included. Generally, a cutoff of 40 yrs is used to define COPD. However, most of the patients included appear to fit the COPD phenotype. Response: The youngest patient recruited was 43 years old. We have updated the inclusion/exclusion criteria in the methods section to say "Inclusion criteria were patients over 40 years of age with both a clinical diagnosis of COPD and a spirometry value indicating obstruction, FEV1/FVC ratio of < 70%", page 9, lines 157-158.
Please add in abstract what type of samples were studied. Response: The following sentence has been added to the abstract "Sputum and oral-pharyngeal swab samples were collected for the isolation of S. pneumoniae", page 3, lines 59-50.
There are contradictory statements regarding correlation with disease severity in the abstract and in "strengths and limitations". Response: We have removed the following sentence from the strengths and limitations section: "Carriage of S. pneumoniae was correlated with the seasons and COPD disease severity".
Intro: The most common etiological agent of COPD exacerbations is not S. Pneumoniae. Nasopharyngeal colonization as a precedent to infection is common in children. It is not known if that is the case in adults and in COPD.
Response: SP is one of the most common bacterial causes of COPD exacerbations along with Haemophilus influenza. We have changed the wording of the introduction, page 6, lines 100-101, to state that "Approximately 50-70% of COPD exacerbations are infectious in origin and one of the most common etiological agent is Streptococcus pneumoniae". Furthermore, we have added three more references, one from 2006, 2014 and 2015, to this sentence. We do not state that SP colonisation precedes COPD exacerbations. We have added the term "invasive" to the sentence in the introduction, page 6, lines 101-103, to say "S. pneumoniae colonises the naso-pharyngeal niche and this colonisation precedes invasive pneumococcal disease".
The sampling in exacerbations was obviously very limited as it appears only 6 exacerbations were studied. Response: We agree and have removed data from unscheduled (exacerbation visits). The numbers of S. pneumoniae isolated is lower than in other studies. Because of the low numbers, the conclusions drawn may not be reliable. Response: We have acknowledged this is the strengths and limitations section by adding the sentence: "The number of S. pneumoniae isolated was low at 16 isolates from 417 samples and the population cohort was small with 133 people recruited, thus limiting the generalisability of the results. However, the carriage incident rate of 3.8% is reflective of results from previous studies", page 5, lines 86-89. In the discussion we mention how our carriage incident rate compares and contrasts with other studies. Furthermore, we have removed the results of the regression analysis as we agree that the numbers are too low to draw any definitive conclusions from this.
The findings suggest that S pneumoniae colonization is associated with less exacerbations. There is no explanation provided for this counter-intuitive observation.
Response: Higher antibiotic usage in non-carriers might have contributed to low carriage rate of S. pneumoniae. We have added a sentence to the results section to acknowledge this, page 13, lines 243-244.
The findings re: non-vaccine serotypes is interesting. Is there literature that vaccination decreases carriage of S. Pneumoniae in adults? Response: We added extra references to the introduction where we state that "There is mounting evidence that the PCV-13 may be of benefit to the adult population that currently receives the PPV- 
GENERAL COMMENTS
The authors have addressed most of my points but have failed to address my first comment and only partially addressed my second.
The failure to address these issues means the study remains flawed.
My first comment is regarding the difference in the concepts of "carriage" in healthy individuals and "colonisation" in COPD subjects. Their response that the data from unscheduled visits was removed does not address this at all. Carriage refers to detection of SP in upper respiratory tract samples (although the term colonisation is also used) whereas colonisation in the context of COPD is used to refer to detection of SP in lower respiratory tract samples (usually sputum). Throughout the paper they randomly alternate between the use of the terms "carriage" and "colonisation" and this makes understanding and interpreting their results very difficult. When comparing their results with published studies they compare with studies in COPD patients that used bronchoscopic samples (17) and studies using NP swabs in healthy adults, children and hospitalised elderly patients (18, 19 and 20) . They do not make clear the enormous differences in these study populations and there is no attempt to discuss how their study population differs from these and what the significance of their findings are, they simply state that carriage rates are similar to their study. My second comment is linked to this as it is clear that there is a mixture of sputum and NP swabs but that the data from the 2 types of samples is included together. They have given the breakdown of the numbers of sputum and NP samples but not the differential results of SP positivity in these samples. They have added the statement "All carriers produced sputum samples (n=15 sputum samples)" and I am unclear what this means and it has raised more questions rather than resolved this issue. Does it mean that the positive samples were only sputum and that all of 129 NP swabs were negative? If this is the case then their results are very different from other studies and this should be discussed. It is not stated whether there were any patients who did not provide any sputum samples during the study. If there were and SP detection rates differ between sputum and NP is it justified to call these subjects non-carriers if no sputum samples were available?
Also if the NP samples were all negative why not simply use the sputum results? This would remove all the ambiguities around carriage and colonisation and would simply be a study of SP colonisation rates in sputum in COPD patients.
REVIEWER

Patrick Mallia Imperial College UK REVIEW RETURNED
23-Feb-2017
GENERAL COMMENTS
My first comment is regarding the difference in the concepts of "carriage" in healthy individuals and "colonisation" in COPD subjects. Their response that the data from unscheduled visits was removed does not address this at all. Carriage refers to detection of SP in upper respiratory tract samples (although the term colonisation is also used) whereas colonisation in the context of COPD is used to refer to detection of SP in lower respiratory tract samples (usually sputum). Throughout the paper they randomly alternate between the use of the terms "carriage" and "colonisation" and this makes understanding and interpreting their results very difficult. When comparing their results with published studies they compare with studies in COPD patients that used bronchoscopic samples (17) and studies using NP swabs in healthy adults, children and hospitalised elderly patients (18, 19 and 20) . They do not make clear the enormous differences in these study populations and there is no attempt to discuss how their study population differs from these and what the significance of their findings are, they simply state that carriage rates are similar to their study. My second comment is linked to this as it is clear that there is a mixture of sputum and NP swabs but that the data from the 2 types of samples is included together. They have given the breakdown of the numbers of sputum and NP samples but not the differential results of SP positivity in these samples. They have added the statement "All carriers produced sputum samples (n=15 sputum samples)" and I am unclear what this means and it has raised more questions rather than resolved this issue. Does it mean that the positive samples were only sputum and that all of 129 NP swabs were negative? If this is the case then their results are very different from other studies and this should be discussed. It is not stated whether there were any patients who did not provide any sputum samples during the study. If there were and SP detection rates differ between sputum and NP is it justified to call these subjects non-carriers if no sputum samples were available? Also if the NP samples were all negative why not simply use the sputum results? This would remove all the ambiguities around carriage and colonisation and would simply be a study of SP colonisation rates in sputum in COPD patients. My first comment is regarding the difference in the concepts of "carriage" in healthy individuals and "colonisation" in COPD subjects. Their response that the data from unscheduled visits was removed does not address this at all. Carriage refers to detection of SP in upper respiratory tract samples (although the term colonisation is also used) whereas colonisation in the context of COPD is used to refer to detection of SP in lower respiratory tract samples (usually sputum). Throughout the paper they randomly alternate between the use of the terms "carriage" and "colonisation" and this makes understanding and interpreting their results very difficult.
VERSION 2 -AUTHOR RESPONSE
-As colonisation in the context of COPD is used to refer to the detection of SP in lower respiratory tract samples (usually sputum) then we have removed any reference to carriage and only referred to the detection of SP in our study cohort as "colonisation". This is due to the fact that all SP isolated came from sputum samples in the study cohort. Please see the tracked changes throughout the manuscript.
When comparing their results with published studies they compare with studies in COPD patients that used bronchoscopic samples (17) and studies using NP swabs in healthy adults, children and hospitalised elderly patients (18, 19 and 20) . They do not make clear the enormous differences in these study populations and there is no attempt to discuss how their study population differs from these and what the significance of their findings are, they simply state that carriage rates are similar to their study.
-Please see the additions made to the discussion in the tracked manuscript on pages 16 and 17 where we address and discuss these differences.
My second comment is linked to this as it is clear that there is a mixture of sputum and NP swabs but that the data from the 2 types of samples is included together. They have given the breakdown of the numbers of sputum and NP samples but not the differential results of SP positivity in these samples. They have added the statement "All carriers produced sputum samples (n=15 sputum samples)" and I am unclear what this means and it has raised more questions rather than resolved this issue.
-Please see the edits made to this sentence, lines 220-222 page 12 of the tracked manuscript.
Does it mean that the positive samples were only sputum and that all of 129 NP swabs were negative? If this is the case then their results are very different from other studies and this should be discussed.
-Please see discussion on this point added to lines 306-312 page 17 of the tracked manuscript.
It is not stated whether there were any patients who did not provide any sputum samples during the study.
-Please see new lines added in at 217-220 page 12 of the tracked manuscript.
If there were and SP detection rates differ between sputum and NP is it justified to call these subjects non-carriers if no sputum samples were available? -Sputum samples were collected in preference to NP samples and where sputum could not be provided, a NP sample was collected. Some participants donated only NP samples. SP was not detected in any NP samples and was detected in just 15 of the 288 sputum samples. We hypothesise that the low detection rate of SP could be partly due to the detection methods available. However, we believe that we are justified in calling those who donated NP samples as non-colonised based on the scope of our detection methods. Please see the additions made to the discussion section where we acknowledge this as a limitation of the study (lines 284-323 in the tracked manuscript).
-Our preference is to leave this data in. There are some participants who solely donated NP samples and removing data from these patients would limit the demographic data that we can present. NP samples are a standard method for SP detection and so we believe data on these samples should be retained in the manuscript. Furthermore, a significant proportion of participants donated a mix of sputum and NP samples throughout the study and by keeping the NP samples in we are getting a more complete picture of the seasonality trends within the cohort. 
GENERAL COMMENTS
The authors have addressed my comments in a satisfactory manner
